Transcriptomic FHITlow/pHER2high signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer

Transcriptomic FHITlow/pHER2high signature as a predictive factor of outcome and immunotherapy response in non-small cell lung cancer

IntroductionIn recent decades, the development of immunotherapy and targeted therapies has considerably improved the outcome of non-small cell lung cancer (NSCLC) patients. Despite these impressive clinical benefits, new biomarkers are needed for an accurate stratification of NSCLC patients and a mo...

Full description

Bibliographic Details
Main Authors: Audrey Brisebarre, Julien Ancel, Théophile Ponchel, Emma Loeffler, Adeline Germain, Véronique Dalstein, Valérian Dormoy, Anne Durlach, Gonzague Delepine, Gaëtan Deslée, Myriam Polette, Béatrice Nawrocki-Raby
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-12-01
Series:Frontiers in Immunology
Subjects:
NSCLC
FHIT
HER2
transcriptomic signature
prognosis
immunotherapy response
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.1058531/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.1058531/full

Similar Items